The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Aminophylline for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Controlled Trial

[+] Article, Author, and Disclosure Information

▸Requests for reprints should be addressed to Kathryn L. Rice, M.D.; Minneapolis VA Medical Center, Department of Medicine, Pulmonary Section (111N), 54th Street and 48th Avenue South; Minneapolis, MN 55417.

© 1987 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1987;107(3):305-309. doi:10.7326/0003-4819-107-2-305
Text Size: A A A

Study Objective: To determine the efficacy of intravenous aminophylline in the treatment of patients hospitalized for exacerbation of chronic obstructive pulmonary disease.

Design: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization.

Patients: Thirty patients admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of chronic obstructive pulmonary disease. Twenty-eight patients completed the study; 2 patients, 1 receiving placebo and 1 receiving aminophylline, were removed from the study because of respiratory failure requiring mechanical ventilation.

Interventions: Patients received either intravenous aminophylline or placebo, in addition to nebulized, inhaled metaproterenol, 0.3 mL of a 5% solution every 6 hours; methylprednisolone, 0.5 mg/kg body weight every 6 hours intravenously; ampicillin, 500 mg orally every 6 hours (tetracycline or trimethoprim-sulfamethoxazole were substituted in penicillin-allergic patients); and supplemental oxygen as needed. Aminophylline infusion rates were adjusted by an unblinded investigator to achieve theophylline levels of 72 to 83 µmol/L. Changes were also made in placebo infusion rates to maintain the double-blind design.

Measurements and Main Results: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after metaproterenol inhalation were measured twice daily by a blinded investigator, who also administered a verbal dyspnea index with a scale of 1 to 10 and questioned patients regarding possible side effects of treatment (tremor, palpitations, nausea, or vomiting). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after metaproterenol treatment and in dyspnea occurred over time in both treatment groups (p < 0.05 for all measurements). However, there were no significant differences between the placebo and aminophylline groups in any of the spirometric measurements or the dyspnea indices (p > 0.5 in all five analyses). The mean increases (± SE) in Po2 of 1.9 (± 0.5) kPa with placebo and 1.7 (± 0.7) kPa with aminophylline and the mean decreases in Pco2 of 0.5 (± 0.4) kPa with placebo and 1.2 (± 0.4) kPa with aminophylline were not significantly different (p > 0.6 for Po2, p > 0.2 for PcO2). Although the difference in the overall incidence of side effects between the two treatment groups, 1 of 13 subjects in the placebo group and 7 of 15 in the aminophylline group was not statistically significant (0.05 < p < 0.10), there was a statistically significant difference in the incidence of gastrointestinal complaints; 6 of 15 and 0 of 13 patients in the aminophylline and placebo groups, respectively (p < 0.05).

Conclusions: We were unable to show that the administration of parenteral aminophylline provides significant additional benefits when added to an otherwise standard treatment regimen in patients with chronic obstructive pulmonary disease exacerbations. Although further benefits from aminophylline in this setting might be shown by studies of much larger numbers of patients, these should be weighed against the demonstrated adverse effects.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.